Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors

Radko Komers, Sharon Anderson, Murray Epstein

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Selective inhibition of cyclooxygenase-2 (COX-2) was proposed as a novel anti-inflammatory and analgesic treatment with a reduced profile of gastrointestinal side effects compared with conventional nonsteroidal anti-Inflammatory drugs (NSAIDs). Although perceived as an inducible enzyme by inflammatory and other stimuli, COX-2 is constitutively expressed in the kidney. In this review, we focus on renal and cardiovascular (CV) physiological and pathophysiological characteristics of COX-2 and renal and CV aspects of treatment with selective COX-2 inhibitors. Both clinical and experimental studies have shown that renal and CV effects of COX-2 inhibitors are similar to those of NSAIDs. These effects include sodium, potassium, and water retention and decreases in renal function, as well as mild to modest increases in blood pressure (BP) and edema. These deleterious effects are amplified in patients with volume and/or sodium depletion. The concomitant administration of COX-2 inhibitors may destabilize BP control in hypertensive patients treated with antihypertensive agents. In contrast to the normal kidney, which could constitute a target for adverse actions of COX-2 inhibitors, recent experimental studies showed increased renal COX-2 expression in several models of renal injury, such as the remnant kidney, renovascular hypertension, and diabetes, and implicated COX-2 in the progression of renal failure. This suggests that COX-2 inhibitors may confer a renoprotective effect in diverse renal disorders. These intriguing formulations must be delineated further in appropriately designed prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)1145-1157
Number of pages13
JournalAmerican Journal of Kidney Diseases
Volume38
Issue number6
StatePublished - 2001

Fingerprint

Cyclooxygenase 2 Inhibitors
Kidney
Cyclooxygenase 2
Anti-Inflammatory Agents
Sodium
Blood Pressure
Renovascular Hypertension
Non-Steroidal Anti-Inflammatory Agents
Pharmaceutical Preparations
Antihypertensive Agents
Renal Insufficiency
Edema
Potassium
Clinical Trials
Water

Keywords

  • Blood pressure (BP)
  • Cyclooxygenase-2 (COX-2)
  • Hypertension
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Renal
  • Renal dysfunction

ASJC Scopus subject areas

  • Nephrology

Cite this

Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. / Komers, Radko; Anderson, Sharon; Epstein, Murray.

In: American Journal of Kidney Diseases, Vol. 38, No. 6, 2001, p. 1145-1157.

Research output: Contribution to journalArticle

@article{0b2b18cfdb6e44c7879125d66df852b3,
title = "Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors",
abstract = "Selective inhibition of cyclooxygenase-2 (COX-2) was proposed as a novel anti-inflammatory and analgesic treatment with a reduced profile of gastrointestinal side effects compared with conventional nonsteroidal anti-Inflammatory drugs (NSAIDs). Although perceived as an inducible enzyme by inflammatory and other stimuli, COX-2 is constitutively expressed in the kidney. In this review, we focus on renal and cardiovascular (CV) physiological and pathophysiological characteristics of COX-2 and renal and CV aspects of treatment with selective COX-2 inhibitors. Both clinical and experimental studies have shown that renal and CV effects of COX-2 inhibitors are similar to those of NSAIDs. These effects include sodium, potassium, and water retention and decreases in renal function, as well as mild to modest increases in blood pressure (BP) and edema. These deleterious effects are amplified in patients with volume and/or sodium depletion. The concomitant administration of COX-2 inhibitors may destabilize BP control in hypertensive patients treated with antihypertensive agents. In contrast to the normal kidney, which could constitute a target for adverse actions of COX-2 inhibitors, recent experimental studies showed increased renal COX-2 expression in several models of renal injury, such as the remnant kidney, renovascular hypertension, and diabetes, and implicated COX-2 in the progression of renal failure. This suggests that COX-2 inhibitors may confer a renoprotective effect in diverse renal disorders. These intriguing formulations must be delineated further in appropriately designed prospective clinical trials.",
keywords = "Blood pressure (BP), Cyclooxygenase-2 (COX-2), Hypertension, Nonsteroidal anti-inflammatory drugs (NSAIDs), Renal, Renal dysfunction",
author = "Radko Komers and Sharon Anderson and Murray Epstein",
year = "2001",
language = "English (US)",
volume = "38",
pages = "1145--1157",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors

AU - Komers, Radko

AU - Anderson, Sharon

AU - Epstein, Murray

PY - 2001

Y1 - 2001

N2 - Selective inhibition of cyclooxygenase-2 (COX-2) was proposed as a novel anti-inflammatory and analgesic treatment with a reduced profile of gastrointestinal side effects compared with conventional nonsteroidal anti-Inflammatory drugs (NSAIDs). Although perceived as an inducible enzyme by inflammatory and other stimuli, COX-2 is constitutively expressed in the kidney. In this review, we focus on renal and cardiovascular (CV) physiological and pathophysiological characteristics of COX-2 and renal and CV aspects of treatment with selective COX-2 inhibitors. Both clinical and experimental studies have shown that renal and CV effects of COX-2 inhibitors are similar to those of NSAIDs. These effects include sodium, potassium, and water retention and decreases in renal function, as well as mild to modest increases in blood pressure (BP) and edema. These deleterious effects are amplified in patients with volume and/or sodium depletion. The concomitant administration of COX-2 inhibitors may destabilize BP control in hypertensive patients treated with antihypertensive agents. In contrast to the normal kidney, which could constitute a target for adverse actions of COX-2 inhibitors, recent experimental studies showed increased renal COX-2 expression in several models of renal injury, such as the remnant kidney, renovascular hypertension, and diabetes, and implicated COX-2 in the progression of renal failure. This suggests that COX-2 inhibitors may confer a renoprotective effect in diverse renal disorders. These intriguing formulations must be delineated further in appropriately designed prospective clinical trials.

AB - Selective inhibition of cyclooxygenase-2 (COX-2) was proposed as a novel anti-inflammatory and analgesic treatment with a reduced profile of gastrointestinal side effects compared with conventional nonsteroidal anti-Inflammatory drugs (NSAIDs). Although perceived as an inducible enzyme by inflammatory and other stimuli, COX-2 is constitutively expressed in the kidney. In this review, we focus on renal and cardiovascular (CV) physiological and pathophysiological characteristics of COX-2 and renal and CV aspects of treatment with selective COX-2 inhibitors. Both clinical and experimental studies have shown that renal and CV effects of COX-2 inhibitors are similar to those of NSAIDs. These effects include sodium, potassium, and water retention and decreases in renal function, as well as mild to modest increases in blood pressure (BP) and edema. These deleterious effects are amplified in patients with volume and/or sodium depletion. The concomitant administration of COX-2 inhibitors may destabilize BP control in hypertensive patients treated with antihypertensive agents. In contrast to the normal kidney, which could constitute a target for adverse actions of COX-2 inhibitors, recent experimental studies showed increased renal COX-2 expression in several models of renal injury, such as the remnant kidney, renovascular hypertension, and diabetes, and implicated COX-2 in the progression of renal failure. This suggests that COX-2 inhibitors may confer a renoprotective effect in diverse renal disorders. These intriguing formulations must be delineated further in appropriately designed prospective clinical trials.

KW - Blood pressure (BP)

KW - Cyclooxygenase-2 (COX-2)

KW - Hypertension

KW - Nonsteroidal anti-inflammatory drugs (NSAIDs)

KW - Renal

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0035722949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035722949&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1145

EP - 1157

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -